Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 49
  • Journal CiteScore: 11.20
  • Journal Impact Factor: 8.24
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Abstract

Development and Validation of HPTLC method for the estimation of Sitagliptin Phosphate and Simvastatin in bulk and Marketed Formulation

Rathod Sonali , Patil Pallavi, Chopade Vittal

Method describes a development and validation of HPTLC method for the estimation of sitagliptin phosphate and simvastatin in bulk and marketed formulation. This employs a precoated silica gel 60 F254 (0.2 mm thickness) on aluminium sheets and mobile phase chloroform: methanol in the ratio of 8:2 v/v, having chamber saturation for 20 min at room temperature. The developing chamber was run up to 8cm. The Rf values were found to be 0.13 and 0.75 for sitagliptin phosphate and simvastatin respectively. The plate was scanned and quantified at 217 nm. The linear detector response was observed between 2000 ng/spot to 7000 ng/spot and 250 ng/spot to 750 ng/spot for sitagliptin phosphate and simvastatin respectively. The method so developed was validated for its accuracy and precision. The LOD and LOQ were found to be 660, 2000 ng/spot and 50, 150 ng/spot, respectively for sitagliptin phosphate and simvastatin .The recovery was carried out by standard addition method. The Average recovery was found to be 92.80 % and 98.01 % for sitagliptin phosphate and simvastatin respectively.